<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416715</url>
  </required_header>
  <id_info>
    <org_study_id>6346</org_study_id>
    <secondary_id>NCI-2010-00621</secondary_id>
    <nct_id>NCT00416715</nct_id>
  </id_info>
  <brief_title>Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer</brief_title>
  <official_title>A Pilot Study of Vitamin D Deficiency and Myalgias, Arthralgias and/or Joint Stiffness Associated With Letrozole (FemaraÂ® )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying vitamin D deficiency, muscle pain, joint pain, and joint
      stiffness in postmenopausal women receiving letrozole for stage I-III breast cancer. Learning
      about vitamin D deficiency and muscle pain, joint pain, and joint stiffness in patients
      receiving letrozole for breast cancer may help doctors plan treatment and may help patients
      live more comfortably
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the rate of vitamin D deficiency in breast cancer patients who experience
      myalgias, arthralgias and/or joint stiffness following initiation of adjuvant letrozole
      treatment.

      SECONDARY OBJECTIVES:

      I. To determine if there is a correlation between letrozole serum levels and the development
      of myalgias, arthralgias and/or joint stiffness.

      II. To assess if vitamin D supplementation may alleviate myalgias, arthralgias and/or joint
      stiffness associated with letrozole in those subjects with vitamin D deficiency.

      OUTLINE:

      Patients receive letrozole orally (PO) once daily (QD). Patients, who experience muscle pain,
      joint pain, or joint stiffness that requires an intervention and who are found to be vitamin
      D deficient, also receive calcium PO and vitamin D3 PO. Treatment continues for up to 28
      weeks in the absence of disease progression or unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Early Breast Cancer Patients Prescribed Adjuvant Letrozole That Are Vitamin D Deficient and Who Experience Myalgias, Arthralgias and/or Joint Stiffness</measure>
    <time_frame>Baseline and 1 month post vitamin D repletion</time_frame>
    <description>Count of early breast cancer patients prescribed adjuvant letrozole that are vitamin D deficient and who experience myalgias, arthralgias and/or joint stiffness, assessed at baseline and 1 month after vitamin D repletion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Letrozole Serum Levels Before and After Vitamin D Repletion</measure>
    <time_frame>Baseline and 1 month post vitamin D repletion</time_frame>
    <description>Letrezole serum level concentration in patients that were vitamin D deficient and experienced myalgias, arthralgias and/or joint stiffness.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Arthralgia</condition>
  <condition>Musculoskeletal Complications</condition>
  <condition>Pain</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (letrozole)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness that requires an intervention and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (letrozole)</arm_group_label>
    <other_name>CGS 20267</other_name>
    <other_name>Femara</other_name>
    <other_name>LTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium carbonate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (letrozole)</arm_group_label>
    <other_name>CaCO3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Treatment (letrozole)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium citrate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (letrozole)</arm_group_label>
    <other_name>Acicontral</other_name>
    <other_name>CALCIT</other_name>
    <other_name>Citracal</other_name>
    <other_name>Tricalcium Citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium glucarate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (letrozole)</arm_group_label>
    <other_name>antacidin</other_name>
    <other_name>calcium D-glucarate</other_name>
    <other_name>calcium D-saccharate</other_name>
    <other_name>CGT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium gluconate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (letrozole)</arm_group_label>
    <other_name>Calcium D-gluconate</other_name>
    <other_name>CALGLUC</other_name>
    <other_name>Calglucon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (letrozole)</arm_group_label>
    <other_name>Calciol</other_name>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>assessment of therapy complications</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (letrozole)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>musculoskeletal complications management/prevention</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (letrozole)</arm_group_label>
    <other_name>complications management/prevention, musculoskeletal</other_name>
    <other_name>management/prevention, musculoskeletal complications</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of Stage I, II or III breast
             carcinoma

          -  Patients must be prescribed letrozole for adjuvant breast cancer treatment

          -  Prior adjuvant tamoxifen is permitted

          -  Patients must be postmenopausal; for study purposes, postmenopausal is defined as: a
             prior documented bilateral oophorectomy, or a history of at least 12 months without
             spontaneous menstrual bleeding, or have a persistently postmenopausal estradiol in the
             past 6 months without menses, and clinically in menopause at the judgment of the
             treating physician, or age 60 or older with a prior hysterectomy without oophorectomy,
             or age less than 60 with a prior hysterectomy without oophorectomy (or in whom the
             status of the ovaries is unknown), with a documented FSH level demonstrating
             confirmatory elevation in the postmenopausal range for the lab

        Exclusion Criteria:

          -  Diagnosis of Stage IV breast carcinoma

          -  Pre-existing myalgias, arthralgias and/or joint stiffness &gt;= Grade 1, as defined using
             CTEP CTC identified during baseline physical exam

          -  Inability to understand or cooperate with study procedures

          -  Receipt of investigational drug within 30 days before study entry

          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome

          -  Unwillingness to give informed consent

          -  Unwillingness to participate or inability to comply with the protocol for the duration
             of the study

          -  Patients with serum calcium &gt;= 14 mg/dL

          -  Patients with renal dysfunction defined as glomerular filtration rate &lt;10ml/min
             calculated using Cockroft-Gault equation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannah Linden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <results_first_submitted>April 14, 2017</results_first_submitted>
  <results_first_submitted_qc>June 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 11, 2017</results_first_posted>
  <last_update_submitted>June 10, 2017</last_update_submitted>
  <last_update_submitted_qc>June 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Hannah Linden</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Letrozole)</title>
          <description>Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.
letrozole: Given PO
calcium carbonate: Given PO
laboratory biomarker analysis: Optional correlative studies
calcium citrate: Given PO
calcium glucarate: Given PO
calcium gluconate: Given PO
cholecalciferol: Given PO
assessment of therapy complications: Ancillary studies
musculoskeletal complications management/prevention: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not evaluable for joint aches</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Vitamin D levels not evaluable</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Letrozole)</title>
          <description>Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.
letrozole: Given PO
calcium carbonate: Given PO
laboratory biomarker analysis: Optional correlative studies
calcium citrate: Given PO
calcium glucarate: Given PO
calcium gluconate: Given PO
cholecalciferol: Given PO
assessment of therapy complications: Ancillary studies
musculoskeletal complications management/prevention: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="42" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Early Breast Cancer Patients Prescribed Adjuvant Letrozole That Are Vitamin D Deficient and Who Experience Myalgias, Arthralgias and/or Joint Stiffness</title>
        <description>Count of early breast cancer patients prescribed adjuvant letrozole that are vitamin D deficient and who experience myalgias, arthralgias and/or joint stiffness, assessed at baseline and 1 month after vitamin D repletion.</description>
        <time_frame>Baseline and 1 month post vitamin D repletion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>All patients that are evaluable for joint aches and vitamin D levels.</description>
          </group>
          <group group_id="O2">
            <title>Post Vitamin D Repletion (1 Month)</title>
            <description>Patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Early Breast Cancer Patients Prescribed Adjuvant Letrozole That Are Vitamin D Deficient and Who Experience Myalgias, Arthralgias and/or Joint Stiffness</title>
          <description>Count of early breast cancer patients prescribed adjuvant letrozole that are vitamin D deficient and who experience myalgias, arthralgias and/or joint stiffness, assessed at baseline and 1 month after vitamin D repletion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Letrozole Serum Levels Before and After Vitamin D Repletion</title>
        <description>Letrezole serum level concentration in patients that were vitamin D deficient and experienced myalgias, arthralgias and/or joint stiffness.</description>
        <time_frame>Baseline and 1 month post vitamin D repletion</time_frame>
        <population>Only considering those patients who were baseline vitamin D deficient and experienced myalgias, arthralgias and/or joint stiffness.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Those receiving Letrozole + vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Post Vitamin D Repletion (1 Month)</title>
            <description>Those receiving Letrezole + vitamin D3</description>
          </group>
        </group_list>
        <measure>
          <title>Letrozole Serum Levels Before and After Vitamin D Repletion</title>
          <description>Letrezole serum level concentration in patients that were vitamin D deficient and experienced myalgias, arthralgias and/or joint stiffness.</description>
          <population>Only considering those patients who were baseline vitamin D deficient and experienced myalgias, arthralgias and/or joint stiffness.</population>
          <units>micro-grams/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O2" value="70" lower_limit="69" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Letrezole)</title>
          <description>Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.
letrozole: Given PO
calcium carbonate: Given PO
laboratory biomarker analysis: Optional correlative studies
calcium citrate: Given PO
calcium glucarate: Given PO
calcium gluconate: Given PO
cholecalciferol: Given PO
assessment of therapy complications: Ancillary studies
musculoskeletal complications management/prevention: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Joint aches</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hannah Linden</name_or_title>
      <organization>University of Washington / Seattle Cancer Care Alliance</organization>
      <phone>206-288-6989</phone>
      <email>hmlinden@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

